The shift from Q1 to H1 is a clear change in guidance. It's been clear to us the 10-15 MACE event rate was not very accurate, unless the drug did not work or the patients were much less healthy than the EXAMINE patient population. 

Given our detailed research it's quite clear the drug does work, ergo the patient population has to be deathly ill for the 10-15 MACE event rate to be remotely accurate.

The fact that it's taking longer than the 10-15 MACE event rate suggests we our model is accurate. The additional guidance further adds weight to this view. You can say what you will about the EXAMINE trial data but it makes for a solid base line in the absence of additional information.

Good day.